Preclinical study determines that long-term supplementation with Curcugen is safe.
A new preclinical study published in Biomedical Research International1 confirmed the long-term safety of Curcugen curcumin formulation (from Dolcas Biotech, LLC, based in Landing, NJ). The safety study used a standard series of in vitro and in vivo safety studies, in accordance with OECD guidelines, including the toxicological assessment of acute, oral, and 90-day repeated dosing.
Tests of acute oral toxicity on rats found a median lethal dose (LD50) of greater than 5,000mg/kg body weight of Curcugen. LD50 refers to the dose required to kill half the members of a test population after a specified test duration. Additionally, a sub chronic assessment of Curcugen, as administered to rats over 90 days, resulted in a no observed adverse effect level (NOAEL) at a dose of 2,000mg/kg body weight/day. Moreover, the extract did not elicit any genotoxic or clastogenic effect in genotoxicity tests.
Reference
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
FDA and FTC issue more warning letters to copycat delta-8 THC food products
July 16th 2024The U.S. Food and Drug Administration and Federal Trade Commission have jointly issued warning letters to five companies for selling copycat food products containing delta-8 THC in violation of the Federal Food Drug and Cosmetic Act.